lactosylceramide
lipidLactosylceramide regulates monocyte recruitment and inflammatory signaling, bridging lipid retention and plaque inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleSphingolipid mediator of plaque inflammation, monocyte migration, and atherothrombotic initiation.
Also acts inLipid entry/oxidation, Platelet activation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I26
C — confounder / Type-II40
A — assay feasibility40
E — evidence strength16
T1DI (composite)3
Specificity differential (R−C)-14.2
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only
Literature evidence(3)
- Sphingolipids in Atherosclerosis: Chimeras in Structure and Function.International journal of molecular sciences · 2022 · PMID 36233252 · doi
- Lipidomics analysis of monocytes from patients with acute myocardial infarction reveals lactosylceramide as a new player in monocyte migration.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021 · PMID 33856696 · doi
- Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity.PloS one · 2019 · PMID 31747417 · doi